G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Executive Director - PDM Product Strategy Leader

Full-Time
$302k - $390.8k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PharmD, PhD, MD
Foster City, CA, USA
In Person
Biology & Biotech
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A degree in science, engineering, or a technical field, with at least 16 years of directly relevant professional experience for BA/BS holders or at least 14 years for MA/MS, PhD, PharmD, or MD holders.
  • A demonstrated track record of outcome-oriented team leadership in pharmaceutical manufacturing, supply chain, quality, CMC regulatory, process development, or as part of a cross-functional product team in the broader pharmaceutical industry.
Responsibilities
  • Represent PDM on Gilead asset teams by translating business strategy and drug development vision into the PDM execution plan, raising technical issues, influencing decision-making and strategy, proactively presenting issues and options to strategy teams, ensuring consistent application of enterprise-wide prioritization principles, and ensuring technical perspectives and concerns are reflected in strategic plans for assigned products.
  • Develop and ensure delivery of process, analytical, and formulation development activities, along with regulatory, supply chain, and quality strategies and plans aligned with product core strategies and milestones; develop and own the product technical plan, including timelines, multi-year budgets, and critical deliverables.
  • Ensure end-to-end plan design, execution, and risk identification and mitigation across Technical Development, CMC regulatory, Supply Chain, Manufacturing, and Quality from first-in-human through commercialization, working with the PDM Product Strategy Team and PDM partners.
  • Maximize learnings across the assigned product portfolio, including strategic planning, efficiencies, and lessons learned.
  • Make decisions to direct the product team or, when decisions are outside the team’s scope, escalate them and steer them through appropriate PDM governance mechanisms.
  • Communicate product activities, deliverables, timelines, and resources clearly and promptly to senior leadership across the enterprise.
  • Drive portfolio-level decisions to optimize resource use and maximize value.
  • Translate external insights, including competitive and commercial trends, into PDM objectives that optimize product robustness.
  • Participate in the PDM Product Strategy Leaders community through ongoing strategic coaching and skill development.
  • Coach part-time PDM Product Strategy Leaders, early-career development scientists and engineers, and other product team members to help them learn and succeed in their roles.
Desired Qualifications
  • Strong expertise in antibody-drug conjugates, biologics, and/or small-molecule development and manufacturing.
  • Influence effectively to lead in a highly matrixed environment without direct authority within enterprise asset teams and across PDM.
  • Build cross-functional and enterprise-wide relationships.
  • Apply a strong business-process orientation practically and for maximum impact.
  • Expertise with cGMP manufacturing and regulatory requirements for biologics and/or small molecules.
  • Work in a dynamic environment with multiple products and modalities.
  • Coach and mentor scientists and engineers across functional areas.
  • Communicate interpersonally, verbally, and in writing; synthesize complex situations, illustrate conceptual paths, and facilitate discussions that resolve key issues.
  • Work efficiently and independently in a changing environment.
  • Handle ambiguity and uncertainty effectively.
  • Assume responsibility and accountability for impactful decisions.
  • Apply strong business and strategic skills, including translating high-level product goals into coherent plans for prioritized PDM activities that support and deliver against those goals.

About the company

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
  • Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
  • Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

  • Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
  • Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
  • Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

  • Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
  • Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
  • Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid family time off and paid parental time off
  • Generous 401(k) contribution matching
  • Comprehensive medical plans that cover both physical and mental healthcare
  • Global Wellbeing Reimbursement
  • Time Off
  • Global Volunteer Day
  • Giving Together Program
  • Employee Support Programs
  • Flexible Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 27th, 2026
ETFs sell net $30.4M of Gilead Sciences as AVLV exits $28.3M position

ETFs sold a net $30.4 million of Gilead Sciences (GILD) on Friday, October 23, extending a four-day selling streak. AVLV drove the activity, cutting $28.3 million and leaving it with no shares. More funds bought than sold, with 29 ETFs adding shares and 14 cutting them, but the sellers moved larger amounts. SPY trimmed $10.5 million and XLV sold $7.5 million. Net selling was $2.8 million on October 22, $17.0 million on October 21, and $19.3 million on October 20. ETFs had bought a net $58.2 million on October 19. Gilead has a market cap of $196.8 billion. Trailing 12-month revenue was $30.54 billion, up 6.5% over one year, and the shares have returned 31.62% this year.

Yahoo Finance
Oct 26th, 2026
Biktarvy growth halves to 7% as it drives 48.7% of Gilead's sales

Gilead Sciences' HIV drug Biktarvy is growing more slowly, raising questions about the company's reliance on it. Sales rose 6.8% in fiscal 2025, down from 13.3% a year earlier, and reached $3.8 billion in the second quarter of 2026, up 7%. Biktarvy made up 48.7% of fiscal 2025 revenue. It added about $0.9 billion in sales that year, more than the roughly $0.7 billion by which total revenue grew. Management expects the HIV treatment market to return to annual growth of 2% to 3%. Prevention sales doubled in the second quarter, topping $1 billion for the first time, and Gilead now expects full-year HIV sales to grow 9% to 10%, up from 8%. Gilead trades at 6.4 times sales, against 3.2 for the S&P 500.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Pharmaceutical Technology
Oct 23rd, 2026
Gilead spends $1.28bn on PepStar's potential Icotyde rival.

Gilead spends $1.28bn on PepStar's potential Icotyde rival. Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast. Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 receptor inhibitor, which the company hopes will rival Johnson & Johnson's recently approved therapy Icotyde (icotrokinra). Through this deal, Gilead will hand over $1.275bn upfront to obtain the rights to PepStar's macrocyclic peptide IL-23R inhibitor pill programme. This includes its lead asset, HCXT-2001, which is currently in Phase I trials. While the IL-23R inhibitor class has thus far made its commercial mark in plaque psoriasis, clinical success is now being seen in inflammatory bowel disease (IBD). Gilead is prioritising the latter with HCXT-2001, though the company is yet to specify which specific indications it will pursue. Unlike other options on the market, HCXT-2001 has an extended half-life, leading Gilead's CMO, Dietmar Berger to claim that the drug could offer a "potentially differentiated approach" to the company's burgeoning inflammation pipeline - which is primarily focused on IBD, type 2 inflammatory diseases, lupus and B cell-mediated autoimmune diseases. "We see potential for HCXT-2001 alone or in combination, including with emvistegrast, as a daily oral treatment for people living with IBD," Berger added. Emvistegrast is Gilead's in-house developed α4β7 integrin inhibitor, which is currently in mid-stage development for IBD. The drug has already demonstrated its potential, having recently met its primary endpoint in patients with ulcerative colitis (UC) during the Phase II SWIFT study (NCT06290934). According to Jefferies analysts, this deal is a good move from Gilead as it allows the company to pursue a promising combination. "Proof of concept data from ABBV-266 [a combination of risankizumab and trosunilimab] shows that a4b7 + IL-23 may offer the best clinical remission in patients with prior advanced treatment," they commented. Meanwhile, they add that preclinical pharmacokinetic studies have pointed toward the early favourability of HCXT-2001 versus Icotyde - pointing to early signs of the drug's differentiated potential. Gilead doubles down on dealmaking. Gilead's deal with PepStar is the latest in a string of deals inked by the California-based pharma, which is currently preparing itself for several key patent expiries across its virology portfolio. To bolster its pipeline and bring new promising assets in, Gilead has inked three acquisitions in 2026. This includes its $7.8bn buyout of CAR-T specialist, Arcellx, as well as its takeovers worth up to $5bn and $2.2bn of antibody-drug conjugate (ADC) developer Tubulis and autoimmune T-cell engager (TCE) therapy-focused biotech Ouro Medicines, respectively. In the same vein, Gilead also recently forged a $1.9bn licensing pact with Vir Biotechnologies centred around next-generation TCEs for solid tumours. According to a recent report by GlobalData, parent company of Pharmaceutical Technology, more than half of the 157 surveyed pharmaceutical professionals feel optimistic or very optimistic about industry growth within the next 12 months. Give your business an edge with its leading industry insights.